Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine..
To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2.
DESIGN: Observational multicenter cohort study.
SETTING: A total of 23 acute care hospitals in four states.
PATIENTS: One-hundred eighteen patients admitted between March 13, 2020, and April 16, 2020. Eighty-one patients received tocilizumab, and 37 were untreated and served as a control group.
MEASUREMENTS AND MAIN RESULTS: The main outcome was mortality and was analyzed by timing of tocilizumab dosing. Early dosing was defined as a tocilizumab dose administered prior to or within 1 day of intubation. Late dosing was defined as a dose administered greater than 1 day after intubation. A control group that was treated only with standard of care, and without tocilizumab, was used for comparison. Early tocilizumab therapy was associated with a statistically significant decrease in mortality as compared to patients who were untreated (p = 0.003). Dosing tocilizumab late was associated with an increased mortality compared with the untreated group (p = 0.006).
CONCLUSIONS: Early tocilizumab administration was associated with decreased mortality in critically ill severe acute respiratory syndrome coronavirus-2 patients, but a potential detriment was suggested by dosing later in a patient's course.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Critical care explorations - 3(2021), 4 vom: 01. Apr., Seite e0395 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Petrak, Russell M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytokine storm |
|---|
| Anmerkungen: |
Date Revised 21.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1097/CCE.0000000000000395 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32373071X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32373071X | ||
| 003 | DE-627 | ||
| 005 | 20231225184818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CCE.0000000000000395 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM32373071X | ||
| 035 | |a (NLM)33817660 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petrak, Russell M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. | ||
| 520 | |a To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2 | ||
| 520 | |a DESIGN: Observational multicenter cohort study | ||
| 520 | |a SETTING: A total of 23 acute care hospitals in four states | ||
| 520 | |a PATIENTS: One-hundred eighteen patients admitted between March 13, 2020, and April 16, 2020. Eighty-one patients received tocilizumab, and 37 were untreated and served as a control group | ||
| 520 | |a MEASUREMENTS AND MAIN RESULTS: The main outcome was mortality and was analyzed by timing of tocilizumab dosing. Early dosing was defined as a tocilizumab dose administered prior to or within 1 day of intubation. Late dosing was defined as a dose administered greater than 1 day after intubation. A control group that was treated only with standard of care, and without tocilizumab, was used for comparison. Early tocilizumab therapy was associated with a statistically significant decrease in mortality as compared to patients who were untreated (p = 0.003). Dosing tocilizumab late was associated with an increased mortality compared with the untreated group (p = 0.006) | ||
| 520 | |a CONCLUSIONS: Early tocilizumab administration was associated with decreased mortality in critically ill severe acute respiratory syndrome coronavirus-2 patients, but a potential detriment was suggested by dosing later in a patient's course | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cytokine storm | |
| 650 | 4 | |a mechanical ventilation | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus-2 | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a Van Hise, Nicholas W |e verfasserin |4 aut | |
| 700 | 1 | |a Skorodin, Nathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Fliegelman, Robert M |e verfasserin |4 aut | |
| 700 | 1 | |a Chundi, Vishnu |e verfasserin |4 aut | |
| 700 | 1 | |a Didwania, Vishal |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Harting, Brian P |e verfasserin |4 aut | |
| 700 | 1 | |a Hines, David W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care explorations |d 2019 |g 3(2021), 4 vom: 01. Apr., Seite e0395 |w (DE-627)NLM300504969 |x 2639-8028 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:e0395 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CCE.0000000000000395 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2021 |e 4 |b 01 |c 04 |h e0395 | ||